Analysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study [0.03%]
糖尿病预防计划结果研究中长期随访的随机临床试验脱离分配方案治疗分析：二甲双胍对糖尿病及其并发症的影响评估
William C Knowler,Qing Pan,Shiyu Shu et al.
William C Knowler et al.
The Diabetes Prevention Program (DPP) was a 3-year randomized clinical trial (RCT) with evaluation of lifestyle and metformin interventions compared with placebo for diabetes prevention in high-risk adults. Both interventions significantly ...
Sight-Threatening Diabetic Retinopathy During and After Pregnancy-A Nationwide Matched-Cohort Study [0.03%]
妊娠期间和产后糖尿病视网膜病变加重——一项全国匹配队列研究
Janni E Larsson,Lonny Stokholm,Toke Bek et al.
Janni E Larsson et al.
Objective: To evaluate the risk of treatment of sight-threatening diabetic retinopathy (DR) defined as panretinal photocoagulation for proliferative DR or anti-vascular endothelial growth factor injections for diabetic ma...
Longitudinal Metabolic Trajectories in Diabetes Prevention Program Participants Reveal Subgroups With Varying Micro- and Macrovascular Complication Risks [0.03%]
糖尿病预防计划参与者纵向代谢轨迹揭示具有不同微血管和大血管并发症风险的亚组
Emily Kobayashi,Nathaniel J Linden-Santangeli,Nicholas Chan et al.
Emily Kobayashi et al.
Objective: Type 2 diabetes (T2D) and its associated complications develop heterogeneously over decades, but few studies span the progression from prediabetes to clinical events. We investigated whether long-term metabolic...
Prediction of Sarcopenia Onset in Type 2 Diabetes Using Urinary Titin Levels: A Japanese Prospective Cohort Study [0.03%]
利用尿粒线蛋白水平预测2型糖尿病患者肌少症发病：一项日本前瞻性队列研究
Hayato Tanabe,Yoshinori Takiguchi,Rie Tsutsumi et al.
Hayato Tanabe et al.
Objective: The predictive power of urinary titin for incident sarcopenia was studied in Japanese individuals with type 2 diabetes. Research design and met...
Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2 [0.03%]
在SURMOUNT-2研究中， tirzepatide减重效果在基线HbA1c分组的超重或肥胖成人2型糖尿病患者中有显著差异
Naveed Sattar,Gema Frühbeck,Fabrizio Andreelli et al.
Naveed Sattar et al.
Cardiovascular Outcome Trials in Type 1 Diabetes: We Are Not There Yet [0.03%]
1 型糖尿病的心血管结局试验：我们仍需努力
Irl B Hirsch,Robert H Eckel
Irl B Hirsch
Connecting the Spots: Serial Home C-peptide Measurements Paint an Accurate Picture of Change in β-Cell Function [0.03%]
连接点滴：连续的胰岛素C肽测量能准确反映胰岛β细胞功能的变化
Brittany S Bruggeman,Timothy P Foster,Michael J Haller
Brittany S Bruggeman
Emma Rose McGlone,Omar Khan
Emma Rose McGlone
Response to Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489-493 [0.03%]
李等关于胰高血糖素样肽1受体激动剂心血管结局的系统评价和meta分析的回信：亚洲人 vs 白种人以及糖尿病与超重/肥胖患者的随机临床试验比较疗效
Matthew M Y Lee,Darren K McGuire,Naveed Sattar
Matthew M Y Lee